Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Fresolimumab in Adults With Osteogenesis Imperfecta
NCT03064074Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Nov 2017
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of fresolimumab in osteogenesis imperfecta (OI) (4 arms), sponsored by Baylor College of Medicine. Primary endpoint: Number of Participants With Treatment-related Adverse Events at 12 months. Started Nov 2017; status: completed.
02
Drugs
fresolimumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT03064074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03064074.